ITF Pharma GmbH
Pharmaceutical Companies · München
ITF Pharma GmbH is a pharmaceutical company based in München, Bavaria, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
ITF Pharma GmbH Address & Contact
Company profile
1938
Founded
1.000+ (Italfarmaco Group global)
Employees
ITF Pharma GmbH Overview
ITF Pharma GmbH is the German subsidiary of the Italian pharmaceutical company Italfarmaco S.p.A. (ITF), which focuses on the research and development of therapies for specialized indications. With its headquarters in Munich, ITF Pharma has established itself as a competent partner in the field of pharmaceutical supply. The company is particularly active in the treatment of rare diseases, which represents a significant difference in the therapeutic landscape.
Heart Failure and Muscle Disorders
For the treatment of hepatic veno-occlusive disease following stem cell transplants, ITF is particularly known for its product Defitelio (Defibrotide). This therapy has proven necessary to address severe complications that can be dangerous for patients in critical health conditions. In addition, the company focuses on Deflazacort formulations, which play an essential role in the therapy of Duchenne muscular dystrophy. This rare neurological disease requires targeted therapeutic approaches for which ITF Pharma provides innovative solutions.
The company's product range also includes specialty products for the fields of hematology and neurology, highlighting ITF Pharma's expertise in these areas. Through significant investments in research and development, ITF is taking an important step towards improving the quality of life for patients suffering from muscular dystrophies and other complex diseases. A particular emphasis is placed on the longitudinal study of therapy combinations and their efficiency to improve prospects for affected individuals.
Regulatory Classification and Market Access
ITF Pharma operates in a highly regulated market and adheres to the strict guidelines of the European Medicines Agency (EMA) as well as the German Federal Institute for Drugs and Medical Devices (BfArM). These regulations are crucial to ensure the safety and efficacy of the products offered. Close collaboration with research institutions and clinical trials enables ITF to bring new therapeutic approaches to market more quickly. The company has all the necessary approvals for its products, allowing patients to benefit from advanced treatments.
Location Munich
ITF Pharma has strategically chosen its location in Munich, as the city is considered a significant center for biomedical research and development. Proximity to leading research institutions, such as the Helmholtz Center Munich, allows ITF Pharma to pursue innovative approaches in medical research through collaboration and scientific exchange. From its Munich location, ITF Pharma supports hematology centers, pediatric clinics, and neuromuscular centers in Germany, which not only underlines the regional importance of the company but also its contribution to healthcare in Germany. The diverse networking opportunities in the region and access to renowned professionals in medicine and science promote the development of therapies specifically tailored to the needs of patient groups.
Special Features and Commitment
A central aspect of ITF Pharma's corporate philosophy is the commitment to informing and supporting patients and relatives suffering from rare diseases. The company regularly initiates information events and workshops to foster exchange between experts, patients, and family members. To support research, close collaboration with patient organizations is also pursued to enable direct dialogue and valuable insights into patient needs.
ITF Pharma pursues a sustainable business practice that encompasses both ecological and social responsibility. Initiatives to reduce the ecological footprint in production and logistics, as well as projects to support education and research in the Munich region, are part of the corporate self-understanding and the company's long-term strategy. Through such measures, ITF Pharma ensures that it not only provides medical solutions but also actively contributes to society.
More pharmaceutical companies in Germany | pharmaceutical companies in Munich | pharmaceutical companies for rare diseases
```Frequently asked questions about ITF Pharma GmbH
What does ITF Pharma GmbH do?
ITF Pharma GmbH gehört zur italienischen Italpharmako Gruppe. Sie stellt Medikamente her and offers medizinische Lösungen and patientsservice. Als erstes hat sie ein Medikament zur Behandlung of venösen Thromboembolien for den German Markt entworfen. Frauengesandheit is ein weiterer Geschäftsbereich, the Frauen in jethe Lebensphase understützen soll.
More Pharmaceutical Companies in München
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.